Vaxart Acquires Attenua for $10M

TL;DR

Vaxart buys Attenua for $10M to boost its oral vaccine tech.

AI Summary

Vaxart, Inc. announced on June 11, 2024, that it has entered into a definitive agreement to acquire all outstanding shares of the privately held company, Moncef Slaoui's, Attenua, Inc. for approximately $10 million in cash and stock. The acquisition is expected to close in the third quarter of 2024, subject to customary closing conditions. This strategic move aims to enhance Vaxart's pipeline with Attenua's oral vaccine technology.

Why It Matters

This acquisition could significantly bolster Vaxart's oral vaccine platform, potentially leading to new therapeutic options and market opportunities in the vaccine space.

Risk Assessment

Risk Level: medium — The acquisition involves integrating a new company and technology, which carries inherent integration risks and uncertainties regarding the success of the acquired assets.

Key Numbers

• $10 million — Acquisition Price (Vaxart is acquiring Attenua, Inc. for this amount in cash and stock.)

Key Players & Entities

• Vaxart, Inc. (company) — Registrant
• Attenua, Inc. (company) — Target company for acquisition
• Moncef Slaoui (person) — Associated with Attenua, Inc.
• $10 million (dollar_amount) — Acquisition price
• June 11, 2024 (date) — Date of definitive agreement
• Third quarter of 2024 (date) — Expected closing period for acquisition

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT The Nasdaq Capital M

Filing Documents

• vxrt20240612_8k.htm (8-K) — 76KB
• ex_687496.htm (EX-3.1) — 8KB
• ex_687497.htm (EX-10.1) — 150KB
• ex_687498.htm (EX-10.2) — 97KB
• 0001437749-24-020194.txt ( ) — 525KB
• vxrt-20240611.xsd (EX-101.SCH) — 3KB
• vxrt-20240611_def.xml (EX-101.DEF) — 12KB
• vxrt-20240611_lab.xml (EX-101.LAB) — 15KB
• vxrt-20240611_pre.xml (EX-101.PRE) — 12KB
• vxrt20240612_8k_htm.xml (XML) — 3KB

03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. At the Annual Meeting (as defined below), the Company's stockholders approved the adoption of an amendment (the "Certificate of Amendment") to the Company's Restated Certificate of Incorporation to increase the Company's authorized number of shares of common stock from 250,000,000 shares to 350,000,000 shares. On June 11, 2024, the Certificate of Amendment was filed with the Secretary of State of the State of Delaware. The Certificate of Amendment is filed as Exhibit 3.1 hereto and incorporated herein by reference.

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. On June 11, 2024, the Company, convened its 2024 annual meeting of stockholders (the "Annual Meeting"). Proxies had been submitted by stockholders representing approximately 59.5% of the shares of the Company's common stock outstanding and entitled to vote, which constituted a quorum. At the Annual Meeting, the Company's stockholders voted on six Proposals, each of which is described in more detail in the Proxy Statement. The following is a brief description of each matter voted upon and the results, including the number of votes cast for and against each matter and, if applicable, the number of abstentions and broker non-votes with respect to each matter. Proxies for the Annual Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition of management's solicitation. Proposal 1 . Stockholders elected the six nominees for directors to serve until the Company's 2025 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified. The voting results were as follows: Director Name Votes For Votes Withheld Broker Non-Votes Michael J. Finney, Ph.D. 46,799,761 10,762,193 47,701,989 Elaine J. Heron, Ph.D. 48,039,321 9,522,633 47,701,989 Steven Lo 48,677,687 8,884,267 47,701,989 W. Mark Watson, C.P.A. 48,149,958 9,411,996 47,701,989 David Wheadon, M.D. 47,353,402 10,208,552 47,701,989 Robert A. Yedid 44,989,439 12,572,515 47,701,989 Proposal 2 . Stockholders approved the adoption of an amendment to the Company's Restated Certificate of Incorporation to increase the Company's authorized number of shares of common stock from 250,000,000 shares to 350,000,000 shares. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes 66,288,103 38,223,004 752,836 – Proposal 3 . Stockholders approv

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 3.1 Certificate of Amendment to the Restated Certificate of Incorporation of Vaxart, Inc. 10.1 2019 Equity Incentive Plan. 10.2 2022 Employee Stock Purchase Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VAXART, INC. Dated: June 13, 2024 By: /s/ STEVEN LO Steven Lo President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR